Top

Published in:

01-09-2010 | Clinical Trial Report

The Use of Single Versus Dual Antiplatelet Therapy Beyond 1 Year Following Drug-Eluting Stent Implantation

Authors: Matthew E. Wiisanen, David J. Moliterno

Published in: Current Cardiology Reports | Issue 5/2010

Excerpt

Park SJ, Park DW, Kim YH, et al.: Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 2010, 362:1374–1382. …

Ong AT, Hoye A, Aoki J, et al.: Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 2005, 45:947–953.CrossRefPubMed

Burzotta F, Parma A, Pristipino C, et al.: Angiographic and clinical outcome of invasively managed patients with thrombosed coronary bare metal or drug-eluting stents: the OPTIMIST study. Eur Heart J 2008, 29:3011–3021.CrossRefPubMed

Iakovou I, Schmidt T, Bonizzoni E, et al.: Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005, 293:2126–2130.CrossRefPubMed

Spertus JA, Kettelkamp R, Vance C, et al.: Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 2006, 113:2803–2809.CrossRefPubMed

Airoldi F, Colombo A, Morici N, et al.: Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007, 116:745–754.CrossRefPubMed

van Werkum JW, Heestermans AA, Zomer AC, et al.: Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol 2009, 53:1399–1409.CrossRefPubMed

Park DW, Yun SC, Lee SW, et al.: Stent thrombosis, clinical events and influence of prolonged clopidogrel use after placement of drug-eluting stent. JACC Cardiovasc Interv 2008, 1:494–503.CrossRefPubMed

ClinicalTrials.gov: The Dual Antiplatelet Study NCT00977938. Available at http://www.clinicaltrials.gov/ct2/show/NCT00977938?term=dual+antiplatelet+therapy&rank=1. Accessed May 6, 2010.

ClinicalTrials.gov: Second Generation Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month—Dual Antiplatelet Therapy NCT00944333. Available at http://www.clinicaltrials.gov/ct2/show/NCT00944333?term=dual+antiplatelet+therapy&rank=6. Accessed May 6, 2010.

10.

ClinicalTrials.gov: EDUCATE: The MEDTRONIC Endeavor Drug Eluting Stenting: Understanding Care, Antiplatelet Agents and Thrombotic Events NCT01069003. Available at http://www.clinicaltrials.gov/ct2/show/NCT01069003?term=dual+antiplatelet+therapy&rank=7. Accessed May 6, 2010.

11.

ClinicalTrials.gov: Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation (OPTIDUAL) NCT00822536. Available at http://www.clinicaltrials.gov/ct2/show/NCT00822536?term=dual+antiplatelet+therapy&rank=10. Accessed on May 8, 2010.

12.

ClinicalTrials.gov: XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort (XVU-AV DAPT) NCT01106534. Available at http://www.clinicaltrials.gov/ct2/show/NCT01106534?term=dual+antiplatelet+therapy&rank=11. Accessed on May 8, 2010.

13.

ClinicalTrials.gov: CYPRESS—CYPheR for Evaluating Sustained Safety NCT00954707. Available at http://www.clinicaltrials.gov/ct2/show/NCT00954707?term=dual+antiplatelet+therapy&rank=12. Accessed on May 8, 2010.

14.

ClinicalTrials.gov: Safety and Efficacy of Six Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) NCT00661206. Available at http://www.clinicaltrials.gov/ct2/show/NCT00661206?term=dual+antiplatelet+therapy&rank=16. Accessed on May 8, 2010.

15.

ClinicalTrials.gov: TAXUS Libertē Post Approval Study NCT00997503. Available at http://www.clinicaltrials.gov/ct2/show/NCT00997503?term=dual+antiplatelet+therapy&rank=21. Accessed on May 8, 2010.

16.

ClinicalTrials.gov: Optimized Duration of Clopidogrel Therapy Following Treatment With the Endeavor Zotarolimus—Eluting Stent in the Real World Clinical Practice—Optimize Trial (OPTIMIZE) NCT01113372. Available at http://www.clinicaltrials.gov/ct2/show/NCT01113372?term=dual+antiplatelet+therapy&rank=32. Accessed on May 8, 2010.

17.

ClinicalTrials.gov: Study of Optimal Clopidogrel Duration in Patients Receiving Drug Eluting Stents (SCORE Trial) NCT00781573. Available at http://www.clinicaltrials.gov/ct2/show/NCT00781573?term=dual+antiplatelet+therapy&rank=40. Accessed on May 8, 2010.

18.

ClinicalTrials.gov: Assessment of Dual Antiplatelet Therapy With Drug Eluting Stents (ADAPT-DES) NCT00638794. Available at http://www.clinicaltrials.gov/ct2/show/NCT00638794?term=dual+antiplatelet+therapy&rank=9. Accessed on May 6, 2010.

19.

ClinicalTrials.gov: Scripps Evaluation of Antiplatelet Therapies for Intermediate Duration With the Endeavor Stent (Seaside) (SEASIDE) NCT00963781. Available at http://www.clinicaltrials.gov/ct2/show/NCT00963781?term=dual+antiplatelet+therapy&rank=13. Accessed on May 8, 2010.

20.

ClinicalTrials.gov: Brazil Xience V Everolimus-Eluting Coronary Stent System “Real-World” Outcomes Registry (BRAVO) NCT00989066. Available at http://www.clinicaltrials.gov/ct2/show/NCT00989066?term=dual+antiplatelet+therapy&rank=39. Accessed on May 8, 2010.

Title: The Use of Single Versus Dual Antiplatelet Therapy Beyond 1 Year Following Drug-Eluting Stent Implantation
Authors: Matthew E. Wiisanen
David J. Moliterno
Publication date: 01-09-2010
Publisher: Current Science Inc.
Published in: Current Cardiology Reports / Issue 5/2010
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI: https://doi.org/10.1007/s11886-010-0128-3

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

At a glance: The STEP trials

Springer Medicine

The Use of Single Versus Dual Antiplatelet Therapy Beyond 1 Year Following Drug-Eluting Stent Implantation

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 5/2010

Erratum to: The Use of Nuclear Imaging for Cardiac Resynchronization Therapy

Thrombectomy During Primary Angioplasty: Methods, Devices, and Clinical Trial Data

Cardiac Resynchronization Therapy in Mild Heart Failure: A Review of the REVERSE and MADIT-CRT Trials

Update on Transcatheter Aortic Valve Implantation

Ablation of Idiopathic Ventricular Tachycardia

Percutaneous Mitral Valve Interventions: Overview of New Approaches

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page